School Readiness in Children with Type 1 Diabetes
Launched by ARIFE AKBULUT · Nov 1, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "School Readiness in Children with Type 1 Diabetes," is looking at how type 1 diabetes affects young children's ability to get ready for school. Researchers want to understand how motor skills (like using their hands), sensory processing (how they respond to things like touch and sound), and overall quality of life impact these children's participation in daily activities and, ultimately, their readiness for school. This study aims to help identify ways to support preschoolers with type 1 diabetes as they prepare for this important transition.
To be eligible for this trial, children need to be between 60 to 78 months old and have been diagnosed with type 1 diabetes within the last six months. It's important to note that children who have other developmental disorders, like cerebral palsy or Down syndrome, or those who are starting the first grade cannot participate. While the trial is not yet recruiting participants, those who join can expect to contribute to valuable research that may improve support for children with diabetes as they get ready for school.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Having been diagnosed with Type 1 DM in the last 6 months (for type 1 diabetes group) Being 60-78 months old
- Exclusion Criteria:
- • - Having any neurodevelopmental disorder in addition to diabetes (EX: cerebral palsy, down syndrome, muscular dystrophies..)
- • Starting 1st grade
About Arife Akbulut
Arife Akbulut is a dedicated clinical trial sponsor focused on advancing medical research and enhancing patient care through innovative clinical studies. With a commitment to ethical practices and rigorous scientific standards, the organization collaborates with healthcare professionals, research institutions, and regulatory bodies to design and implement trials that address unmet medical needs. Leveraging a wealth of expertise in clinical development, Arife Akbulut aims to accelerate the delivery of safe and effective therapies, ensuring that the trial process prioritizes patient safety and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported